

Receipt date: 01/25/2006

10555831-2006 1611  
 MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO  <b>INFORMATION DISCLOSURE          STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete if Known	
		Application Number	Base on PCT/JP/02800
		Confirmation Number	Unknown
		Filing Date	January 25, 2006
		First Named Inventor	Junya TOGUCHIDA
		Art Unit	Unknown
Examiner Name	Unknown	Attorney Docket Number	Q92863
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 6,133,230	A	10-17-2000	UNIV. QUEENS KINGSTON

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		WO	03/45371	A1	06-05-2003	PFIZER PROD. INC.	
		JP	<del>2001-220357</del>	<del>A</del>	<del>08-14-2001</del>	<del>Pfizer Products Inc.</del>	
		WO	98/58911	A2	12-30-1998	PFIZER INC	
		JP	<del>2000-507061</del>	<del>A</del>	<del>06-27-2000</del>	<del>PFIZER INC</del>	
		JP	<del>2001-220357</del>	<del>A</del>	<del>08-14-2001</del>	<del>Pfizer Products Inc.</del>	
		JP	<del>11-193268</del>	<del>A</del>	<del>07-21-1999</del>	<del>Ono Pharmaceutical Co., Ltd.</del>	
		WO	02/92064	A2	11-21-2002	MEDICAL RES COUNCIL	
		JP	<del>2001-527063</del>	<del>A</del>	<del>12-25-2001</del>	<del>Ono Pharmaceutical Co., Ltd.</del>	
		JP	<del>2000-05755</del>	<del>A</del>	<del>04-04-2000</del>	<del>Ono Pharmaceutical Co., Ltd.</del>	
		JP	<del>2000-128858</del>	<del>A</del>	<del>05-09-2000</del>	<del>Ono Pharmaceutical Co., Ltd.</del>	
		WO	98/34916	A1	08-13-1998	ONO PHARM CO. LTD.	
		JP	<del>2002-179595</del>	<del>A</del>	<del>06-26-2002</del>	<del>Pfizer Products Inc.</del>	
		JP	<del>6-227085</del>	<del>A</del>	<del>08-16-1994</del>	<del>G.D. Searle &amp; Co.</del>	
		WO	02/16311	A1	02-28-2002	ONO PHARM CO. LTD.	
		WO	<del>02/20462</del>	<del>A1</del>	<del>03-14-2002</del>	<del>ONO PHARM CO. LTD.</del>	
		WO	03/16254	A1	02-27-2002	ONO PHARM CO. LTD.	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>	
		AJ DE-BRUM-FERNANDES, et al., "Characterization of the PGE2 receptor subtype in bovine chondrocytes in culture", Br. J. Pharmacol., 1996, pp. 1597-1604, Vol. 118, No. 7		
		VM PARALKAR, et al., "An EP2 receptor-selective prostaglandin E2 agonist induces bone healing", Proc. Natl. Acad. Sci. USA, May 27, 2003, pp. 6736-6740		
		F DEL TORO JR, et al., "Characterization of prostaglandin E(2) receptors and their role in 24,25-(OH)(2)2(3)-mediated effects on resting zone chondrocytes", J. Cell. Physiol., 2000, pp. 196-208, Vol. 182, No. 2		
		U. SUZUWA, et al., "The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for the respective EPs.", Endocrinology, 2000, pp. 1554-1559, Vol. 141, No. 4		
		E. ROSADO, et al., "Transforming growth factor-β1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways.", Biochim. Biophys. Acta, 2002, pp. 1-15, Vol. 1590, No. 1-3		
		VL SYLVIA, et al., "Transforming growth factor-β1 regulation of resting zone chondrocytes is mediated by two separate but interacting pathways.", Biochim. Biophys. Acta, 2000, pp/ 311-324, Vol. 1496, No. 2-3		
		VL SYLVIA, et al., "Characterization of PGE <sub>2</sub> receptors (EP) and their role as mediators of 1α,25-(OH) <sub>2</sub> D <sub>3</sub> effects on growth zone chondrocytes.", J. Steroid Biochem. Mol. Biol., 2001, pp. 261-274, Vol. 78, No.3		
		JM MCCOY, et al. "The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis.", J. Clin. Invest., 2002, pp. 651-658, Vol. 110, No. 5		
Examiner Signature		/Joseph Kudla/	Date Considered	06/30/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to indicate here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /J.K./